Sun Pharma Releases ESG Overview for FY 2025-26

Sun Pharmaceutical Industries Limited has submitted its ESG Overview for the financial year 2025-26. The report, prepared with reference to GRI Standards 2021 and externally assured by DNV Business Assurance India Private Limited, covers 44 manufacturing and R&D locations, representing 84% of operational sites for EHS indicators and 100% for other indicators. The overview details the company's performance and initiatives across environmental, social, and governance aspects, including corporate governance, ethics, risk management, product quality, energy management, emissions, waste, water management, and stakeholder engagement. Sun Pharma, a global specialty generic pharmaceutical leader with USD 6.6 billion in revenues, operates across approximately 100 countries.